In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Acer Therapeutics (ACER), with a price target of $10.00. The company’s shares closed last Monday at $3.31, close to its 52-week low of $1.87.
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.7% and a 29.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acer Therapeutics with a $10.00 average price target.
See today’s analyst top recommended stocks >>
Based on Acer Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.25 million. In comparison, last year the company had a GAAP net loss of $3.97 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome.
